What Happened
Employer coverage of GLP-1 drugs for weight loss fell for the first time in three years, according to a benefits survey released October 28 by WTW.
The firm's 2026 Best Practices in Healthcare Survey, fielded over the summer, found that 53% of employers with more than 100 employees now cover GLP-1s for weight management, down from 57% a year earlier. The decline is not settled policy. Among employers still covering the drugs, 30% said they are considering eliminating coverage. Of the employers that have dropped coverage or are weighing it, 91% cited cost.
The direction of travel is visible in the 2027 plan year. Roughly 14% of employers have already dropped GLP-1 coverage or plan to drop it for 2027, and WTW projects employer health costs climbing about 11% into 2027 — the fastest pace in more than two decades.
Who Is Affected
Employees on self-funded plans, who typically discover the change during open enrollment rather than at the pharmacy counter. Also affected: the telehealth and compounding sellers positioned to absorb patients who lose coverage, and the clinicians who inherit them mid-treatment.
Timeline
- Summer 2026 — WTW fields the survey; cost projections are compiled.
- October 28, 2026 — Results released: coverage down four points, 30% of remaining plans considering cuts.
- Late 2026 — Open enrollment decisions lock in 2027 formularies.
- January 2027 — Terminations take effect for the roughly 14% of employers that have dropped or plan to drop coverage.
What This Means for Researchers
Insurance loss is the most documented on-ramp to unregulated supply. When an approved product becomes unaffordable, patients migrate to compounded versions, gray-market vials and imported alternatives — the same channels that produced the sterility recalls, dosing errors and 1,700-plus federal problem reports documented over the past two years. For anyone tracking peptide quality, coverage policy is upstream of every safety signal.
The practical consequence is that "is this product what it says it is" stops being an academic question for a much larger population, and lot-level testing becomes the only check a patient can actually run.
How to Verify Your Peptides
- Request a third-party certificate of analysis with a lot number that matches the vial.
- Confirm sterility testing and the supplier's licensure before the first injection, not after.
- Weigh the labeled concentration against tested concentration — discrepancies are the common failure.
- Our testing hub explains how to read a COA, what an accredited lab report includes, and what a supplier cannot fake.
Safe Alternatives
If coverage is ending, the options worth pricing are an FDA-approved product under a manufacturer savings program, a lower-cost approved alternative chosen with a clinician, or — for research use only — a supplier that publishes lot-level testing. Our peptide reference pages separate approved drugs from research compounds, and the vendor directory lists suppliers with documented testing practices.
Sources
Industry reports; regulatory announcements; benefits survey data published by WTW (October 28, 2026); federal adverse-event reporting summarized in prior PepsReview coverage.